BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18048966)

  • 1. Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma.
    Weber DG; Taeger D; Pesch B; Kraus T; Brüning T; Johnen G
    Cancer Biomark; 2007; 3(6):287-92. PubMed ID: 18048966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MESOMARK: a potential test for malignant pleural mesothelioma.
    Beyer HL; Geschwindt RD; Glover CL; Tran L; Hellstrom I; Hellstrom KE; Miller MC; Verch T; Allard WJ; Pass HI; Sardesai NY
    Clin Chem; 2007 Apr; 53(4):666-72. PubMed ID: 17289801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
    Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
    J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.
    Rai AJ; Flores RM; Mathew A; Gonzalez-Espinoza R; Bott M; Ladanyi M; Rusch V; Fleisher M
    Clin Chem Lab Med; 2010 Feb; 48(2):271-8. PubMed ID: 20131968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.
    Segawa T; Hagiwara Y; Ishikawa K; Aoki N; Maeda M; Shiomi K; Hino O
    Biochem Biophys Res Commun; 2008 May; 369(3):915-8. PubMed ID: 18328258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
    Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma.
    Franko A; Dolzan V; Kovac V; Arneric N; Dodic-Fikfak M
    Dis Markers; 2012; 32(2):123-31. PubMed ID: 22377706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.
    Filiberti R; Marroni P; Spigno F; Merlo DF; Mortara V; Caruso P; Cioè A; Michelazzi L; Bruzzone A; Bobbio B; Simonassi C; Del Corso L; Galli R; Racchi O; Dini G; Linares R; Mencoboni M
    Oncology; 2014; 86(1):33-43. PubMed ID: 24401539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results.
    Di Serio F; Fontana A; Loizzi M; Capotorto G; Maggiolini P; Mera E; Bisceglia L; Molinini R
    Clin Chem Lab Med; 2007; 45(5):634-8. PubMed ID: 17484626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
    Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer.
    Cristaudo A; Foddis R; Vivaldi A; Guglielmi G; Dipalma N; Filiberti R; Neri M; Ceppi M; Paganuzzi M; Ivaldi GP; Mencoboni M; Canessa PA; Ambrosino N; Chella A; Mutti L; Puntoni R
    Clin Cancer Res; 2007 Sep; 13(17):5076-81. PubMed ID: 17785560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual predictors of increased serum mesothelin in asbestos-exposed workers.
    Filiberti R; Marroni P; Mencoboni M; Mortara V; Caruso P; Cioè A; Michelazzi L; Merlo DF; Bruzzone A; Bobbio B; Del Corso L; Galli R; Taveggia P; Dini G; Spigno F
    Med Oncol; 2013 Mar; 30(1):422. PubMed ID: 23277285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
    De Santi C; Pucci P; Bonotti A; Melaiu O; Cipollini M; Silvestri R; Vymetalkova V; Barone E; Paolicchi E; Corrado A; Lepori I; Dell'Anno I; Pellè L; Vodicka P; Mutti L; Foddis R; Cristaudo A; Gemignani F; Landi S
    Occup Environ Med; 2017 Jun; 74(6):456-463. PubMed ID: 28343162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
    Luo L; Shi HZ; Liang QL; Jiang J; Qin SM; Deng JM
    Respir Med; 2010 Jan; 104(1):149-56. PubMed ID: 19945835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating SMRP and CA-125 before and after pleurectomy decortication for pleural mesothelioma.
    Paajanen J; Sadek A; Richards WG; Xie Y; Mazzola E; Sidopoulos K; Kuckelman J; Gill RR; Bueno R
    Thorac Cancer; 2024 May; 15(15):1237-1245. PubMed ID: 38627917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble mesothelin-related protein--a blood test for mesothelioma.
    Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I
    Lung Cancer; 2005 Jul; 49 Suppl 1():S109-11. PubMed ID: 15950789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers in malignant mesothelioma: diagnostic and prognostic role of soluble mesothelin-related peptide.
    Dipalma N; Luisi V; Di Serio F; Fontana A; Maggiolini P; Licchelli B; Mera E; Bisceglia L; Galise I; Loizzi M; Pizzigallo MA; Molinini R; Vimercati L
    Int J Biol Markers; 2011; 26(3):160-5. PubMed ID: 21928246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.